Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOPHYLLIN vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40% bound to albumin; binding is nonlinear and decreases at higher serum concentrations.
85-90% bound to albumin.
0.4-0.7 L/kg, approximating total body water (0.45 L/kg in adults). Vd is increased in neonates (0.6 L/kg) and decreased in obesity (0.3-0.4 L/kg) due to reduced lean body mass.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 90-100%; Oral sustained-release: 80-100% relative to immediate-release; Rectal solution: 100%; Rectal suppository: 60-80% (erratic).
Oral: 60-80% (first-pass metabolism reduces bioavailability).
For GFR <30 m L/min: reduce maintenance dose by 50%; consider monitoring serum concentrations.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 75%; Child-Pugh Class C: avoid use or use with extreme caution with 80% dose reduction.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
IV loading dose: 5-7 mg/kg over 20-30 minutes; maintenance IV infusion: 0.5-1 mg/kg/hour for ages 1-9 years, 0.4-0.7 mg/kg/hour for ages 9-16 years; oral: 10-20 mg/kg/day in divided doses every 6-8 hours, maximum 600 mg/day.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Elderly patients: reduce loading dose to 4-5 mg/kg; maintenance dose 0.2-0.3 mg/kg/hour IV or 200-400 mg/day oral; monitor serum theophylline levels closely due to decreased clearance.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
None explicitly required by FDA, but use with caution due to narrow therapeutic index and potential for severe toxicity.
No FDA boxed warning exists for this combination product.
Narrow therapeutic index; monitor serum concentrations regularly. Risk of arrhythmias, seizures, and gastrointestinal bleeding. Use lower doses in heart failure, liver disease, and elderly. Avoid abrupt discontinuation due to withdrawal symptoms.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to xanthines, active seizure disorders, severe arrhythmias, and uncontrolled hyperthyroidism.
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing theophylline levels. Limit caffeine intake (coffee, tea, cola) as it may add to theophylline's stimulant effects. High-fat meals may delay absorption; take consistently with or without food.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third trimesters: no known adverse fetal effects. However, use only if clearly needed.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Excreted into breast milk; M/P ratio approximately 0.6-0.8. Relative infant dose is low (<10% of maternal weight-adjusted dose). No reports of adverse effects in breastfed infants. Caution advised in preterm or ill infants.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Pregnancy reduces theophylline clearance by 30-50%, especially in the third trimester. Dose may need reduction by up to 50% to maintain therapeutic levels. Monitor levels closely and adjust accordingly. Postpartum clearance rapidly returns to prepregnancy levels, requiring dose increase to avoid subtherapeutic levels.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
LANOPHYLLIN is a fixed-dose combination of lansoprazole, a proton pump inhibitor, and theophylline, a methylxanthine bronchodilator. Monitor serum theophylline levels due to lansoprazole's potential to inhibit CYP1A2, increasing theophylline toxicity risk. Avoid in patients with hepatic impairment or acute asthma exacerbation. Taper theophylline to prevent withdrawal seizures.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take this medication exactly as prescribed, usually once daily in the morning.,Swallow the capsule whole; do not crush or chew.,Avoid drinking alcohol or consuming grapefruit products while on this medication.,Report symptoms like nausea, vomiting, palpitations, or seizures immediately.,Do not stop abruptly; consult your doctor for gradual dose reduction.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOPHYLLIN vs ACCURBRON, answered by our medical review team.
LANOPHYLLIN is a Bronchodilator that works by Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOPHYLLIN and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOPHYLLIN is: 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOPHYLLIN and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOPHYLLIN is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.